Media Thread, page-214

let's make a simple comparison with Herceptin and Hervaxx as they both target HER2 positive cancers (Herceptin targets breast cancer)

Herceptin
7 billion in sales per annum ((USD) or 9.5 billion AUD
Hazard ratio of .64 equates to a 36% increased survivability compared to chemo alone or radiation
Side effects include potentially fatal cardiac and lung failure and a sh#t ton of minor issues (headaches, diarrhea, nausea, chills, fever, infections, insomnia etc etc)

Hervaxx
0 sales as IMU are in clinical trials
interim hazard ratio of .418 equates to a 58% increased survivability compared to chemo alone
no recorded adverse side effects

No wonder the IDMC has decided to pull this up early by halving the required patients based on this "statistically significant" HR, remember Hervaxx is a "platform" so can be designed to target breast, ovarian, gastric etc as LC mention ("our Hervaxx platform has now been validated" in her words)

Do you own research, but for me it's a no brainer, I haven't factored in our other "shots on goal" such as CF33 or PD-1

I cannot understand the current price action, my shares are not for sale under $2 as I'm playing the long game.